BioE Stem Cell Featured in Experimental Hematology Review Article
About Potential of Cord Blood Stem Cells
Dec 18 2007, 6:35 AM EST
News source: Business Wire
BioE(R), Inc., a biomedical company that provides enabling, high-
quality human stem cells for drug discovery and therapeutic research,
announced today a review article published in the December 2007 issue
(Vol. 35, Issue 12) of the journal Experimental Hematology features
its Multi-Lineage Progenitor Cell(TM) (MLPC(TM)) as a cord blood stem
cell with potential for therapeutic and cell regeneration
applications.
Dan Collins, Ph.D., executive vice president and chief scientific
officer for BioE, contributed to the paper with leading physicians
and researchers from Morgan Stanley Children's Hospital of NewYork-
Presbyterian and Columbia University Medical Center. Specifically,
the review's authors cite the MLPC's controlled and extensive
differentiation capabilities; genetic stability and lack of teratoma
formation; and ability to develop pure clonal cell lines as key
characteristics that define the stem cell's high utility compared to
embryonic stem cells and adult-source stem cells.
"BioE's MLPC stem cell shows great promise as a critical cord blood
stem cell that in the future could be utilized to regenerate a
variety of tissues including cardiac, skin, nervous, pancreatic
(insulin producing) among others," said senior author Mitchell S.
Cairo, M.D., chief, Blood & Marrow Transplantation at Morgan Stanley
Children's Hospital and professor of pediatrics, medicine and
pathology at Columbia University College of Physicians and
Surgeons. "As stem cell research continues to advance on many fronts,
cord blood stem cells -- including the MLPC -- likely will provide
researchers a viable source of cells to help repair numerous tissues
within the body in the near term. Compared to embryonic and adult
stem cells, cord blood stem cells are widely available, and their
immaturity and flexibility should produce larger quantities of
homogeneous tissues or cells for transplantation and help minimize
rejection of generated tissue when transplanted into a mismatched
host."
While cord blood stem cells were once considered functionally
limited, the review's authors discuss a voluminous body of research
demonstrating their ability to differentiate into non-blood-related
cells and tissue lineages. For example, research shows the cord blood-
derived MLPC stem cell has the ability to turn into cells
representative of the three different embryonic germinal layers,
including liver and pancreatic precursor cells, terminally
differentiated liver cells, lung cells, fat cells, cartilage cells,
bone cells, skeletal muscle, blood vessels, neural stem cells and
nerve cells.
"The MLPC is an attractive cord blood stem cell for many researchers
due to its significant differentiation capabilities, easy
accessibility and ability to maintain genetic stability through 80
doublings," Dr. Collins said. "The clonally derived cells can be
expanded into therapeutically relevant numbers of cells, thus
providing a pure population of identically behaving cells."
Current MLPC Adoption
During the past two years, more than 100 academic research
institutions, corporate laboratories and pharmaceutical organizations
located around the world have licensed the MLPC from BioE for a
variety of stem cell and regenerative medicine research and drug
development purposes. Additionally, BioE is engaged in a variety of
collaborative stem cell research partnerships to further advance its
understanding of the MLPC. Current MLPC research partners and areas
of study include:
-- University of Minnesota (Minneapolis) -- Respiratory disease and
lung injury; teratoma formation; augmentation of hematopoietic
engraftment and reduction of graft versus host disease (GVHD) and
autoimmune disorders.
-- University of New South Wales and South Eastern Sydney Illawarra
Area Health Service/Diabetes Transplant Unit (Sydney, Australia) --
Diabetes.
-- University of Texas/M. D. Anderson Cancer Center (Austin, Texas) --
Cancer treatments; anti-tumor protein delivery.
-- Phillips Plastics (Prescott, Wisc.) -- Stem cell therapeutics for
orthopedic (bone, cartilage, tendons, ligaments and spinal discs)
applications.
-- University of Newcastle (Newcastle, U.K.) -- Other novel umbilical
cord blood cells sourced using BioE's stem cell enrichment platform.
"We are pleased to see the MLPC recognized as a cord blood stem cell
at the forefront of stem cell research," Dr. Collins said. "While
further and continued research is required, we are hopeful that the
MLPC has the characteristics and functionality needed to one day help
impact medicine and improve patient care."
Additional Review Paper Details
Along with describing research involving the MLPC stem cell, the
Experimental Hematology paper summarizes cord blood stem cell
benefits and additional "in vitro and in vivo studies examining
umbilical cord blood stem cells and their potential use for
therapeutic application for non-hematopoietic tissue and cell
regeneration.
Society for Hematology and Stem Cells.
http://www.genengne
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Earn your degree in as few as 2 years - Advance your career with an AS, BS, MS degree - College-Finder.net.
Fed Lowers Rates Again - Think you pay you much for your mortgage? No SSN Required - Estimate New Payment.
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
No comments:
Post a Comment